Aims To develop prediction models for identifying cases with poor visual outcomes after surgery for primary rhegmatogenous ...

Correspondence to Dr Abhijit Sinha Roy, Department of Imaging, Biomechanics and Telemedicine, Narayana Nethralaya Foundation, Bangalore 560010, India; asroy27{at}yahoo.com Aims To develop a ...

Objective The objective of this study was to assess the efficacy of low-dose atropine 0.01% in controlling myopia progression among Indian children over a 2-year period. Methods This retrospective ...

Drusen volume and reticular pseudodrusen volume from optical coherence tomography with deep learning as risk factors for progression to late age-related macular degeneration in eyes with reticular ...

Department of Ophthalmology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA Dr S M Hariprasad, Department of Ophthalmology and Visual Science, Vitreoretinal Service ...

2 Hainan Eye Hospital and Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Haikou, China Background Myopia is a pervasive global public health concern, ...

Correspondence to Ian E Murdoch, UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK; i.murdoch{at}ucl.ac.uk Background/aims To compare the accuracy of self-obtained, ...

Correspondence to Dr Mingzhi Zhang, Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, Guangdong, China; zmz{at}jsiec.org Methods The ...

2 Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria Correspondence to Dr Claus Zehetner, Department of Ophthalmology, Medical University Innsbruck, Anichstr. 35, ...

Correspondence to Theresa M Cooney, Department of Ophthalmology and Visual Sciences, University of Michigan W. K. Kellogg Eye Center, 1000 Wall St, Ann Arbor, MI 48105, USA; tmnairus{at}umich.edu Aim ...

Purpose Myopia is associated with an increased risk of permanent vision loss. The caffeine metabolite 7-methylxanthine (7-MX), licensed in Denmark since 2009 as a treatment to reduce the rate of ...

Purpose Teprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials.